RecruitingPhase 2NCT05548296
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
Sponsor
Acrivon Therapeutics
Enrollment
353 participants
Start Date
Aug 29, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria37
- Participant must be able to give signed, written informed consent.
- Participant must have histologically documented, high-grade endometrial cancer. Arms 1 and 2
- All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (Grade 3 only), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies.
- Arm 3
- Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.
- Treatment History Requirements:
- Arms 1 and 2
- Subject must have received prior platinum-based chemotherapy
- Subject must have received prior anti-PD-(L)1 therapy
- Subject must not have received more than three lines of prior systemic therapy Arm 3
- <!-- -->
- Subject must have received prior platinum-based chemotherapy
- Subject must have received prior anti-PD-(L)1 therapy
- Subject must not have received more than two lines of prior systemic therapy
- Participant must have histologically confirmed metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
- Participant must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator) in a baseline tumor imaging that has been obtained within 28 days of the treatment start. Participant must have radiographic evidence of disease progression based on RECIST v1.1 criteria following the most recent line of treatment.
- Arm 1 and 2 only: Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after written informed consent.
- Newly obtained is defined as a specimen taken after written informed consent is obtained, during the 28-day Screening period.
- Note: Subjects at EU sites are not eligible for Arm 1 and Arm 2
- Participant must be willing to provide an archival tumor tissue block or at least 20 unstained slides, if available.
- Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows:
- Alopecia is accepted.
- Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency).
- Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.
- Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1.
- Participant must have an estimated life expectancy of longer than 3 months.
- Participant must have adequate organ function at Screening, defined as:
- Absolute neutrophil count \> 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening.
- Hemoglobin ≥ 9.0 g/dL.
- Platelets ≥ 150,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening.
- Renal function is defined as Glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m2. Note: GFR may be estimated using site standard methods (e.g., CKD-EPI, MDRD, or Cockcroft-Gault) or measured using 24-hour urine collection or Chrome-EDTA clearance, as per site standard practice.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present.
- Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable.
- Serum albumin ≥ 3 g/dL.
- Participant must have adequate coagulation profile as defined below if not on anticoagulation. If subject is receiving anticoagulation therapy, then subject must be on a stable dose of anticoagulation for ≥ 1 month:
- Prothrombin time within 1.5 x ULN.
- Activated partial thromboplastin time within 1.5 x ULN.
Exclusion Criteria13
- Participant with known symptomatic brain metastases requiring \> 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
- Participant has mesenchymal tumors of the uterus.
- Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.
- Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.
- Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
- Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
- Participant has cardiovascular disease, defined as:
- Uncontrolled hypertension defined as blood pressure \> 160/90 mmHg at Screening confirmed by repeat (medication permitted).
- History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT based on Fridericia's formula (QTcF) \> 450 msec (for men) or \> 470 msec (for women).
- Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction \< 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).
- Participant has a history of major surgery within 4 weeks of Screening.
- Participant has experienced bowel obstruction related to the current cancer within the last 6 months or signs or symptoms of intestinal obstruction, which include nausea, vomiting, or objective radiologic finding of bowel obstruction in the last 4 weeks before the start of the treatment.
- Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368
Interventions
DRUGACR-368
ACR-368 is an experimental drug
DRUGGemcitabine
Sensitization of tumor cells is provided through administration of ULDG
DIAGNOSTIC_TESTOncoSignature
Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy
Locations(90)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05548296
Related Trials
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT05112601136 locations
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT063997579 locations
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
NCT070778761 location
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT069170921 location
PErsonalized TReatment for Endometrial Carcinoma
NCT056552601 location